Portal de Periódicos da CAPES

Results of Three Life‐Span Experimental Carcinogenicity and Anticarcinogenicity Studies on Tamoxifen in Rats

1997; Wiley; Volume: 837; Issue: 1 Linguagem: Inglês

10.1111/j.1749-6632.1997.tb56895.x

1749-6632

C Maltoni, Franco Minardi, Carmine Pinto, Fiorella Belpoggi, Luciano Bua,

Carcinogens and Genotoxicity Assessment

Annals of the New York Academy of SciencesVolume 837, Issue 1 p. 469-512 Results of Three Life-Span Experimental Carcinogenicity and Anticarcinogenicity Studies on Tamoxifen in Rats CESARE MALTONI, CESARE MALTONI Cancer Research Center European Ramazzini Foundation of Oncology and Environmental Sciences Bentivoglio Castle 40010 Bentivoglio (BO), ItalySearch for more papers by this authorFRANCO MINARDI, FRANCO MINARDI European B. Ramazzini Foundation of Oncology and Environmental Sciences Bologna, ItalySearch for more papers by this authorCARMINE PINTO, CARMINE PINTO European B. Ramazzini Foundation of Oncology and Environmental Sciences Bologna, ItalySearch for more papers by this authorFIORELLA BELPOGGI, FIORELLA BELPOGGI European B. Ramazzini Foundation of Oncology and Environmental Sciences Bologna, ItalySearch for more papers by this authorLUCIANO BUA, LUCIANO BUA European B. Ramazzini Foundation of Oncology and Environmental Sciences Bologna, ItalySearch for more papers by this author CESARE MALTONI, CESARE MALTONI Cancer Research Center European Ramazzini Foundation of Oncology and Environmental Sciences Bentivoglio Castle 40010 Bentivoglio (BO), ItalySearch for more papers by this authorFRANCO MINARDI, FRANCO MINARDI European B. Ramazzini Foundation of Oncology and Environmental Sciences Bologna, ItalySearch for more papers by this authorCARMINE PINTO, CARMINE PINTO European B. Ramazzini Foundation of Oncology and Environmental Sciences Bologna, ItalySearch for more papers by this authorFIORELLA BELPOGGI, FIORELLA BELPOGGI European B. Ramazzini Foundation of Oncology and Environmental Sciences Bologna, ItalySearch for more papers by this authorLUCIANO BUA, LUCIANO BUA European B. Ramazzini Foundation of Oncology and Environmental Sciences Bologna, ItalySearch for more papers by this author First published: 08 June 2007 https://doi.org/10.1111/j.1749-6632.1997.tb56895.xCitations: 11AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1 Cole, M. P., C. T. A. Jones & I. D. Ht 1971. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br. J. Cancer 25: 270 – 275. 2 Furr, B. J. A. & V. Cj 1984. The pharmacology and clinical uses of tamoxifen. Pharmacol. & Ther. 25: 127 – 205. 3 Jordan, V. C. 1976. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA- induced rat mammary carcinomata. Eur. J. Cancer 12: 419 – 424. 4 Ludwig Breast Cancer Study Group. 1984. Randomized trial of chemo-endocrine therapy and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastases. Lancet 1: 1256 – 1260. 5 Senanayake, F. 1984. Adjuvant hormonal chemotherapy in early breast cancer: Early results from a controlled trial. Lancet 2: 1148 – 1149. 6 Cummings, F. J., R. Gray, T. E. Davis et al 1985. Adjuvant tamoxifen treatment of elderly women with stage II breast cancer. A double blind comparison with placebo. Ann. Intern. Med. 103: 324 – 329. 7 Palshof, T., B. Carstensen, H. T. Mouridsen et al 1985. Adjuvant endocrine therapy in pre- and postmenopausal women with operable breast cancer. Rev. Endocrine Rel. Cancer 17 (Suppl.): 43 – 50. 8 Rose, C, S. M. Thorpe, K. W. Andersen et al. 1985. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high estrogen receptor values. Lancet 1: 16 – 19. 9 Breast Cancer Trials Committee, Scottish cancer trials office. 1987. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Lancet 2: 171 – 175. 10 Delozier, T., J.-P. Julien, P. Juret et al 1987. Adjuvant tamoxifen in postmenopausal breast cancer: Preliminary results of a randomized trial. Breast Cancer Res. Treat. 7: 105 – 110. 11 Pritchard, K., J. W. Meakin, N. F. Boyd et al 1987. Adjuvant tamoxifen in postmenopausal women with axillary node positive breast cancer: An update. In Adjuvant Therapy of Cancer. S. E. Salmon, Ed.: 391 – 400. Grune and Stratton. Orlando , FL . 12 Rutqvist, I. E., B. Cedermark, U. Glas et al 1987. The Stockholm trial on adjuvant tamoxifen in early breast cancer. Breast Cancer Res. Treat. 10: 255 – 266. 13 Bianco, A. R., C. Gallo, S. Marinelli et al 1988. Adjuvant therapy with tamoxifen in operable breast cancer: 10 year results of the Naples (GUN) study. Lancet 2: 1095 – 1099. 14 CRC Adjuvant Breast Trial Working Party. 1988. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br. J. Cancer 57: 604 – 607. 15 Nolvadex Adjuvant Trial Organization. 1988. Controlled trial of Tamoxifen as a single adjuvant agent in the management of early breast cancer. Br. J. Cancer 57: 608 – 611. 16 Ribeiro, G. & R. Swindell 1988. The Christie Hospital adjuvant tamoxifen trial. Status at 10 years. Br. J. Cancer 57: 601 – 603. 17 Fisher, B., J. Costantino, C. Redmond et al 1989. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med. 320: 479 – 484. 18 Cummings, F. J., R. Gray, D. C. Tormey et al 1993. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: Long-term follow-up and causes of death. J. Clin. Oncol. 11: 29 – 35. 19 Fisher, B., J. Costantino, L. Wickerham et al 1993. Adjuvant therapy for node-negative breast cancer: An update of NSABP findings. Proc. Am. Soc. Clin. Oncol. 12: 79. 20 Jordan, V. C., K. E. Allen & C. J. Dix. 1980. Pharmacology of tamoxifen in laboratory animals. Cancer Treat. Rep. 64: 745 – 759. 21 Pento, J. T., R. A. Magarian & M. M. King 1982. A comparison of the efficacy for antitumor activity of the non-steroidal antiestrogens analog II and tamoxifen in 7,12-dimethylbenz[a]nthracene-induced rat mammary tumors. Cancer Lett. 15: 261 – 269. 22 McCormick, D. L. & R. Cm. 1986. Retinoid-tamoxifen interaction in mammary cancer chemoprevention. Carcinogenesis 7: 193 – 196. 23 Gottardis, M. M. & V. C. Jordan 1987. Antitumor actions of keokifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res. 47: 4020 – 4024. 24 Teelmann, K. & W. Bollag 1988. Therapeutic effects of the arotenoid Ro 15-0778 on chemically-induced rat mammary carcinoma. Eur. J. Cancer Clin. Oncol. 24: 1205 – 1209. 25 Ratko, T. A., C. J. Detrisac, N. M. Dinger, et al 1989. Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res. 49: 4472 – 4476. 26 Jordan, V. C., M. K. Lababidi & D. M. Mirecki. 1990. Anti-oestrogenic and anti- tumour properties of prolonged tamoxifen therapy in C3H/OUJ mice. Eur. J. Cancer 26: 718 – 721. 27 Maltoni, C, C. Pinto & G. Paladini 1988. Project of experimental bioassays on chemoprevention agents performed at the Bologna Institute of Oncology: Report on tamoxifen control of spontaneous mammary tumors on Sprague-Dawley rats. Cancer Invest. 6: 643 – 658. 28 Maltoni, C, M. Soffritti, C. Pinto, et al 1988. II contribute sperimentale alia chemioprevenzione. In Atti del XIV Congresso Nazionale di Oncologia: II ruolo della terapia chirurgica in oncologia. Vol. II. F. Morino, L. Caldarola, A. Mussa, P. Calderini, D. Carretti & C. Maltoni, Eds: 1073-1100. Monduzzi. Bologna . 29 Maltoni, C, C. Pinto, A. Mobiglia et al 1989. La chemioprevenzione dei tumori: Bilanci, ricerche in corso e prospettive. In Aggiornamenti in Oncologia Medica. G. Rasa, C. Maltoni, S. Amato, G. Castiglione, G. Grasso, M. L. Palmeri & F. Cuva, Eds: 3 – 89. Monduzzi. Bologna . 30 Maltoni, C, C. Pinto, M. Soffritti et al 1989. La chemioprevenzione dei tumori della mammella: Acquisizioni disponibili, con particolare riguardo ai dati sperimentali. In I tumori della mammella. C. Maltoni, D. Marrano, S. Rubini, D. F. Rivelli & V. Patella, Eds: 305 – 359. Monduzzi. Bologna . 31 Maltoni, C, F. Minardi, C. Pinto et al 1990. Long-term bioassays on the toxic carcinogenic and tumour chemopreventive effects (particularly on mammary carcinomas) of tamoxifen on Sprague-Dawley rats: Ongoing studies and early results. Acta Oncol. 11: 289 – 305. 32 Maltoni, C, C. Pinto, A. Mobiglia et al 1990. La chemioprevenzione dei tumori: Lo stato attuale delle conoscenze ed il progetto di ricerca dell'Istituto di Oncologia di Bologna. In Aggiornamenti in oncologia medica. T. Battelli, Ed: 111 – 169. Monduzzi. Bologna . 33 Maltoni, C, C. Pinto, M. Soffritti et al 1990. Chemioprevenzione dei tumori della mammella. Argomenti di Oncologia 11: 1 – 22. 34 Maltoni, C, F. Minardi & C. Pinto 1991. II tamoxifen come potenziale agente chemiopreventivo nel carcinoma mammario nella donna: Scenario, presupposti scientifici, recenti acquisizioni sperimentali e studi clinici disponibili e in programmazione. In Progressi in oncologia clinica, Tamoxifene, Vol. I. G. Robustelli della Cuna & F. Pannuti, Eds.: 117 – 138. EDIMES. Pavia . 35 Maltoni, C, F. Minardi, C. Pinto et al 1991. Un nuovo approccio al controllo del carcinoma mammario nella donna: La chemioprevenzione. Adria Medica 2: 11 – 50. 36 Maltoni, C, F. Minardi, C. Pinto et al 1991. La chemioprevenzione del carcinoma mammario: Bilancio delle conoscenze e prospettive. Atti delle Giornate Medico-Chirur-giche Internazionali in onore di Achille Mario Dogliotti, Vol. I: 91 – 172. Minerva Medica. Torino . 37 Maltoni, C, F. Minardi, C. Pinto et al 1992. La chemioprevenzione del carcinoma mammario: Basi scientifiche e orientamenti. In Atti del XVIII Congresso Nazionale di Oncologia, II cancro della mammella alle soglie del Duemila, Vol. I. T. Battelli, P. Manocchi, R. Mattioli, A. Pilone, S. Delprete, S. Rossini, G. De Signoribus, R. R. Silva, D. Carretti & C. Maltoni, Eds: 127 – 142. Monduzzi. Bologna . 38 Maltoni, C, F. Minardi, M. Soffritti et al. 1992. La prevenzione del carcinoma mammario: Presupposti scientifici e programmi. Acta Oncol. 13: 523 – 530. 39 Maltoni, C, F. Minardi, M. Soffritti et al. 1994. The role of experimental research in cancer chemoprevention using human-equivalent animal models: A project on tamoxifen. In Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects. M. Motta & M. Serio, Eds: 319 – 329. Elsevier. Amsterdam . 40 Fisher, B. 1992. The evolution of paradigms for the management of breast cancer: A personal perspective. Cancer Res. 52: 2371 – 2383. 41 Love, R. R. 1993. The National Surgical Adjuvant Breast Project (NSABP) Breast Cancer Prevention Trial revisited. Cancer Epidemiol. Biomarkers Prev. 2: 403 – 407. 42 Lippman, S. M., S. E. Benner & W. K. Hong. 1994. Cancer chemoprevention. J. Clin. Oncol. 12: 851 – 873. 43 Veronesi, U. & C. Maltoni 1992. Protocollo di chemioprevenzione del carcinoma mammario con tamoxifen. 44 Cuzick, J. 1992. Protocol for the UKCCCR National Multicentre Tamoxifen Breast Cancer Prevention Trial. 45 Powles, T. J., A. L. Jones, S. E. Ashley et al 1994. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res. Treat. 31: 73 – 82. 46 Blackburn, A. M., S. A. Amiel, R. R. Millis et al 1984. Tamoxifen and liver damage. Br. Med. J. 289: 288. 47 Clarysse, A. 1985. Hormone-induced tumor flare. Eur. J. Cancer Clin. Oncol. 21: 545 – 547. 48 Diver, J. M., I. M. Jackson & J. D. Fitzgerald. 1986. Letter to the editor, Tamoxifen and non-malignant indication. Lancet 1: 733. 49 Smith, I. 1988. Adjuvant tamoxifen for early breast cancer. Br. J. Cancer 57: 527 – 528. 50 Love, R. R. 1989. Prospects for antiestrogen chemoprevention of breast cancer. J. Natl. Cancer Inst. 82: 18 – 21. 51 Powles, T. J., J. R. Hardy, S. E. Ashley et al. 1989. Chemoprevention of breast cancer. Breast Cancer Res. Treat. 14: 23 – 31. 52 Powles, T. J., J. R. Hardy, S. E. Ashley et al 1989. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br. J. Cancer 60: 126 – 131. 53 Powles, T. J., C. R. Tillyer, A. L. Jones et al 1990. Prevention of breast cancer with tamoxifen-An update on the Royal Marsden Hospital Pilot Programme. Eur. J. Cancer 26: 680 – 684. 54 Fornander, T., L. E. Rutqvist, B. Cedermark et al 1989. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancer. Lancet 1: 117 – 120. 55 Fisher, B., J. P. Costantino, C. K. Redmond et al. 1994. Endometrial cancer in tamoxifentreated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86: 527 – 537. 56 Williams, G. M., M. J. Iatropoulos, M. V. Djordjevic et al 1993. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14: 315 – 317. 57 Greaves, P., R. Goonetilleke, G. Nunn et al 1993. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res. 53: 3919 – 3924. 58 Hard, G. C., M. J. Iatropoulos, K. Jordan et al 1993. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl: CD (BR) rats. Cancer Res. 53: 4534 – 4541. 59 Hirsimaki, P., Y. Hirsimaki, L. Nieminen et al 1993. Tamoxifen induces hepatocellular carcinoma in rat liver: A 1-year study with two antiesttogens. Arch. Toxicol. 67: 49 – 54. 60 Dragan, Y. P., S. Fahey, K. Street et al. 1994. Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats. Breast Cancer Res. Treat. 31: 11 – 25. Citing Literature Volume837, Issue1Preventive strategies for living in a chemical world, a symposium in honor of Irving J. SelikoffDecember 1997Pages 469-512 ReferencesRelatedInformation